Login
$LONA
$3.23 -$0.24 (6.92%) Live

Company Executives

Officer Age In this role 2025 pay Source
Mark Litton Also a director
PRESIDENT and CEO
Title from the Form 4 dated Apr 9, 2026
58 Not stated $1,423,814
Robert Renninger
Chief Financial Officer
42 Since 2025
1 year
Not reported
Javier San Martin
Chief Medical Officer
61 Since 2024
2 years
$810,134
Kevin Church
chief scientific officer
41 Since 2023
3 years
Not reported
Mark Worthington
general counsel
60 Since 2021
5 years
$731,477

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
10
serving now
Independent
9 of 10
stated in the proxy
Average tenure
3.6 years
from year joined
CEO also chairs the board
No
Kelly A. Romano
Director Age On board Independent Committees Other public boards 2025 pay Source
Kelly A. Romano
64 2020
6 years
Independent
Nominating and Corporate Governance · Chair
UGI Corporation, Dorman Products, Inc., Potter Global Technologies $90,657
Mark Litton
58 2021
5 years
Not independent None stated None stated Paid as CEO
James A. Johnson
69 2020
6 years
Independent
Audit · Chair
None stated $70,157
Natalie C. Holles
53 2026
this year
Independent None stated Aura Biosciences Not stated
Frederick P. Callori
58 2026
this year
Independent None stated None stated Not stated
Joseph Edelman
70 2020
6 years
Independent None stated Perceptive Capital Solutions Corp. $49,157
Grant Pickering
58 2022
4 years
Independent None stated Vaxcyte, Inc. $50,157
Peter B. Silverman
48 2026
this year
Independent None stated Kinaset Therapeutic Not stated
Barbara Kosacz
68 2021
5 years
Independent
Compensation · Chair
XOMA Royalty Corporation $59,157
Michael Panzara
59 2022
4 years
Independent
Compliance · Chair
None stated $59,157

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed May 11, 2026
Perceptive Life Sciences Master Fund Ltd.
greater than 5% holder of our common stock prior to the PIPE Transaction; Joseph Edelman, a director, is a managing member of its investment manager
$20.0 million
December 18, 2025

Purchased common stock, pre-funded warrants and Series A and Series B common warrants in the PIPE private placement, together with Perceptive Xontogeny Venture Fund II, LP, for an aggregate purchase price of $20.0 million

Peter B. Silverman
designated to our board of directors by Commodore under the PIPE Securities Purchase Agreement
Amount not stated

Board designation right under the PIPE Securities Purchase Agreement; designee appointed to our board of directors

With Commodore Open in proxy
Natalie C. Holles
designated to our board of directors by TCGX under the PIPE Securities Purchase Agreement
Amount not stated

Board designation right under the PIPE Securities Purchase Agreement; designee appointed to our board of directors

With TCGX Open in proxy
Sermonix Pharmaceuticals, Inc.
an affiliate of Perceptive Advisors held approximately 29% of the outstanding capital stock of Sermonix at the time of entry into the Sermonix License
Approximately $16.8 million
December 18, 2025

Exclusive license to develop and commercialize oral lasofoxifene outside Asia and certain Middle East countries; consideration includes third-party service provider payments and $75,000 per month payments to Sermonix

Sermonix Pharmaceuticals, Inc.
an affiliate of Perceptive Advisors held approximately 29% of the outstanding capital stock of Sermonix at the time of entry into the Sermonix License
Amount not stated
December 18, 2025

Securities purchase agreement under which we issued a pre-funded warrant to purchase 5,502,402 shares of common stock at an exercise price of $0.001 per share, with related registration rights

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support